Northern Trust Corp Decreases Stock Position in Stevanato Group S.p.A. (NYSE:STVN)

Northern Trust Corp trimmed its stake in Stevanato Group S.p.A. (NYSE:STVN) by 55.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 74,887 shares of the company’s stock after selling 94,812 shares during the quarter. Northern Trust Corp’s holdings in Stevanato Group were worth $1,632,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. TimesSquare Capital Management LLC boosted its holdings in shares of Stevanato Group by 114.6% in the 4th quarter. TimesSquare Capital Management LLC now owns 3,288,529 shares of the company’s stock valued at $71,657,000 after purchasing an additional 1,756,100 shares during the last quarter. Jennison Associates LLC purchased a new position in shares of Stevanato Group in the 4th quarter worth $20,239,000. Mutual of America Capital Management LLC acquired a new position in Stevanato Group in the fourth quarter valued at $13,848,000. Ranger Investment Management L.P. acquired a new position in Stevanato Group in the fourth quarter valued at $12,940,000. Finally, Artisan Partners Limited Partnership grew its position in Stevanato Group by 28.7% during the fourth quarter. Artisan Partners Limited Partnership now owns 2,355,799 shares of the company’s stock valued at $51,333,000 after acquiring an additional 524,989 shares during the period.

Stevanato Group Stock Performance

Stevanato Group stock opened at €22.24 ($25.27) on Tuesday. The firm has a market capitalization of $6.74 billion, a PE ratio of 47.32, a price-to-earnings-growth ratio of 7.18 and a beta of 0.51. Stevanato Group S.p.A. has a one year low of €16.56 ($18.82) and a one year high of €25.75 ($29.26). The stock’s 50 day moving average price is €21.73 and its 200 day moving average price is €21.32. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81.

Stevanato Group (NYSE:STVN) last posted its earnings results on Thursday, March 6th. The company reported €0.20 ($0.23) EPS for the quarter, hitting analysts’ consensus estimates of €0.20 ($0.23). The business had revenue of €352.68 million for the quarter, compared to analysts’ expectations of €346.26 million. Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. As a group, sell-side analysts expect that Stevanato Group S.p.A. will post 0.5 EPS for the current fiscal year.

Stevanato Group Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, July 17th. Shareholders of record on Thursday, June 5th will be given a $0.0613 dividend. This is a boost from Stevanato Group’s previous annual dividend of $0.05. This represents a yield of 0.3%. The ex-dividend date of this dividend is Thursday, June 5th. Stevanato Group’s dividend payout ratio is presently 11.76%.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. William Blair reissued an “outperform” rating on shares of Stevanato Group in a research report on Friday, March 7th. Stephens raised shares of Stevanato Group to a “strong-buy” rating in a research report on Monday, April 21st. Finally, UBS Group cut their target price on shares of Stevanato Group from $24.00 to $23.50 and set a “neutral” rating on the stock in a research note on Friday, March 7th. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of €25.70 ($29.20).

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.